Inaugural issue of American Journal of Men's Health

March 09, 2007

Testicular cancer is the most common malignancy among 15-35 year-old young men. Men over 65 tend to get prostate cancer, the second leading cause of cancer death among American men. It's important for researchers and physicians to get as much information on these serious killers as possible so that men can be better informed; which is why the American Journal of Men's Health by SAGE, has published research on both in its very first issue which debuts in March 2007.

One article out of the Behavioral Research Center, American Cancer Society and the Centers for Disease Control and Prevention both out of Atlanta, GA, focuses on a study of testicular cancer in African American men. While testicular cancer screening rates were low for all men, African American men tend to be diagnosed at a later stage of the disease, have higher mortality rates, a higher perception of fatalism and lower overall knowledge about testicular cancer itself. The researchers concluded that raising the public's awareness of testicular cancer would be a feasible goal because it could lessen the racial disparities and lower the mortality rates by encouraging earlier screening and treatment.

The other article by Donald Bailey, PhD, RN from Duke University, and Meredith Wallace, PhD, APRN,BC from Fairfield University, looked at research of early stage prostate cancer among older men and whether "watchful waiting" was a reasonable option to aggressive therapy. Health care providers are divided regarding the best treatment options for prostate cancer and, with no definitive agreement; diagnosed men tend to experience more uncertainty in making treatment decisions. One thing is certain, further work is needed to change the perception that delaying treatment, which may actually be the best option in many cases, is an automatic death sentence.

"Publishing research that can positively affect men's health is the focus of American Journal of Men's Health," commented the journal's editor, Demetrius Porche, DNS, APRN. "These two studies exploring men's cancers illustrate that mission and are examples of the types of cutting-edge information each issue will feature."
The article, "Critical Review: Is Watchful Waiting a Viable Management Option for Older Men with Prostate Cancer?," written by Donald E. Bailey Jr., PhD, RN, and Meredith Wallace, PhD, APRN, BC can be accessed free for a limited time at To access "Testicular Cancer Among African American College Men: Knowledge, Perceived Risk, and Perceptions of Cancer Fatalism," by Barbara D. Powe, PhD, RN, Louie Ross, PhD, Donoria Wilkerson, BS, Patrice Brooks, BA, and Dexter Cooper, MPH, for a limited time, go to Both articles appear in the March 2007 issue of American Journal of Men's Health published by SAGE.

American Journal of Men's Health (AJMH) is a new quarterly journal publishing cutting-edge information about specific issues related to men's health and illness. It features original articles, research briefs, editorials, health policy, legislative updates, and other articles for healthcare providers, patient educators, policy development specialists, researchers, and scholars. Visit

SAGE Publications is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology and medicine. A privately owned corporation, SAGE has principal offices in Los Angeles, London, New Delhi, and Singapore.


Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to